Torren Management
AVBP icon

Torren Management’s ArriVent BioPharma AVBP Stock Holding History

Torren Management’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$999 Hold
33
– – ﹤0.01% 715
2026
Q2 		$1.15K Hold
33
– – ﹤0.01% 711
2026
Q1 		$761 Hold
33
– – ﹤0.01% 797
2025
Q4 		$664 Buy
+33
New +$687 ﹤0.01% 1284

Other funds holding AVBP

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
ALPS Advisors
ALPS Advisors Denver, Colorado $21.8B AUM 17.58% 1-Year Est. Return
Moody Aldrich Partners
Moody Aldrich Partners Marblehead, Massachusetts $523M AUM 75.24% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
Tema ETFs
Tema ETFs New York $2.69B AUM 42.96% 1-Year Est. Return

Torren Management's AVBP Position: Q3 2026 in Review

Torren Management held its ArriVent BioPharma (AVBP) position steady in Q3 2026 at 33 shares worth $999. The position accounts for ﹤0.01% of the portfolio, ranked #715.

Torren Management first reported a position in AVBP in Q4 2025 and has held it in 4 quarters since. The position peaked at $1.15K in Q2 2026. 45 funds tracked by Wall St. Rank hold AVBP as of Q3 2026.

  • Torren Management held 33 shares of ArriVent BioPharma worth $999 as of Q3 2026.
  • Torren Management left its ArriVent BioPharma share count unchanged in Q3 2026.
  • ArriVent BioPharma made up ﹤0.01% of Torren Management's portfolio in Q3 2026, its #715 holding.
  • Torren Management first reported a position in ArriVent BioPharma in Q4 2025 and has held it in 4 quarters since.
  • Torren Management's ArriVent BioPharma position peaked at $1.15K in Q2 2026.
  • 45 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q3 2026.

Based on Torren Management's 13F filing for Q3 2026, filed 29 Oct 2026.